Gepon & ezrin-derived peptidesГепон
What is it?
An ezrin-related peptide family, distinct from thymic extracts and marrow-derived myelopeptides. The current record establishes a patent identity trail.
Research context
An ezrin-related peptide family, distinct from thymic extracts and marrow-derived myelopeptides. The current record establishes a patent identity trail.
What the studies found
No study findings are ready to summarize for this preparation. Linked archival leads still need original-source verification; this is not evidence that no research exists.
- Working classification
- Peptide research family
- Research collection
- Peptide bioregulation · editorial grouping
- Institutional provenance
- Not established for this compound record
- Last evidence review
- Full evidence review pending; source-check scope appears with each publication below.
What do we know?
- Human research
- —No human treatment trial assessed for this family
- Study methods
- —Member-specific studies; patents and archival leads identified separately
- Independent replication
- —Independent replication not established by the records collected here
- Source access
- —Primary abstracts, selected full texts, patents and explicit retrieval targets
- Safety evidence
- —Cell and animal effects do not establish human safety; analogues may differ
These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.
Inside this research family
Grouping supports navigation. It does not imply equivalent composition, mechanisms, effectiveness or safety.
| Member | Identity | What the source supports |
|---|---|---|
| Gepon / HEP1 | TEKKRRETVEREKE | Parent peptide identified in the patent source. Ezrin-derived peptides and pharmaceutical compositions — US9682140B2 ↗ |
| HP-V2 | GEKKRRETVEREGG | Modified peptide; not equivalent to the parent. Ezrin-derived peptides and pharmaceutical compositions — US9682140B2 ↗ |
| Shorter fragments | TEKKR / RETVEREKE | Patent-discussed fragments; separate identity and evidence required. Ezrin-derived peptides and pharmaceutical compositions — US9682140B2 ↗ |
Interpretation and open questions
Clinical claims and current registration status are not established by this patent-only record.
Linked sources
Explore the research map and unresolved leads ↗
Ezrin-derived peptides and pharmaceutical compositions — US9682140B2
· Primary source linked above
The patent distinguishes HEP1/Gepon (TEKKRRETVEREKE), its shorter fragments and the modified HP-V2 sequence GEKKRRETVEREGG. Identity and patent proposals do not establish equivalent clinical effects.
- Population / setting
- Ezrin-related patent chemistry and experimental examples
- What was checked
- Selected original-source text checked; full methodological review pending.
Limitations & review scope
- Modified sequences and mixtures must not inherit Gepon outcomes.
- Clinical evidence appraisal remains pending.
Source checked 2026-10-05. This is a source-linked record, not a completed evidence review.